Xilio Therapeutics Income Statement (2020-2026) | XLO

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
2.36M2.26M1.72M2.93M8.08M19.07M13.69M12.65M
Operating items
Research & Development (Quarter)
17.75M10.47M11.35M14.92M16.25M13.04M15.00M16.13M13.22M11.05M11.74M10.40M11.22M10.76M8.84M8.27M15.33M14.32M18.12M19.83M
Selling, General & Administrative (Quarter)
5.26M5.49M8.20M6.30M8.31M7.17M8.17M7.39M6.90M6.31M6.39M6.14M5.82M6.31M6.52M8.52M7.12M6.67M7.40M6.93M
Restructuring Costs (Quarter)
0.95M0.03M-0.04M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
23.01M15.96M19.56M21.22M24.55M20.21M23.17M23.53M20.12M17.36M18.13M17.49M17.06M17.02M15.35M16.78M22.45M21.00M25.52M26.76M
Operating Income (Quarter)
-23.01M-15.96M-19.56M-21.22M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
EBIT (Quarter)
-23.01M-15.96M-19.56M-21.22M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Non-operating items
Other Non Operating Income (Quarter)
-0.17M-0.29M-0.14M-0.13M-0.06M0.42M0.70M0.88M0.76M0.61M0.47M0.28M0.78M0.74M0.54M0.59M-1.43M1.02M0.92M1.28M
Non Operating Income (Quarter)
-0.17M-0.29M-0.14M-0.13M-0.06M0.42M0.70M0.88M0.76M0.61M0.47M0.28M0.78M0.74M0.54M0.59M-1.48M-14.36M22.20M4.58M
Net income details
EBT (Quarter)
-23.11M-31.76M-19.66M-21.42M-24.82M-20.43M-24.42M-23.73M-20.19M-17.40M-19.21M-17.80M-14.88M-14.86M-13.91M-13.91M-14.40M-2.00M-11.86M-14.13M
Profit After Tax (Quarter)
-23.18M-16.25M-19.70M-21.35M-24.61M-19.79M-22.44M-22.60M-19.36M-16.75M-17.66M-17.20M-13.93M-14.02M-13.09M-13.27M-15.84M-16.29M10.36M-9.53M
Income from Continuing Operations (Quarter)
-23.11M-31.76M-19.66M-21.42M-24.82M-20.43M-24.42M-23.73M-20.19M-17.40M-19.21M-17.80M-14.88M-14.86M-13.91M-13.91M-14.40M-2.00M-11.86M-14.13M
Consolidated Net Income (Quarter)
-23.11M-31.76M-19.66M-21.42M-24.82M-20.43M-24.42M-23.73M-20.19M-17.40M-19.21M-17.80M-14.88M-14.86M-13.91M-13.91M-14.40M-2.00M-11.86M-14.13M
Income towards Parent Company (Quarter)
-23.11M-31.76M-19.66M-21.42M-24.82M-20.43M-24.42M-23.73M-20.19M-17.40M-19.21M-17.80M-14.88M-14.86M-13.91M-13.91M-14.40M-2.00M-11.86M-14.13M
Net Income towards Common Stockholders (Quarter)
-23.11M-31.76M-19.66M-21.42M-24.82M-20.43M-24.42M-23.73M-20.19M-17.40M-19.21M-17.80M-14.88M-14.86M-13.91M-13.91M-14.40M-2.00M-11.86M-14.13M
Additional items
EPS (Basic) (Quarter)
-439.25-582.02-49.08-10.96-12.69-10.44-12.48-12.11-10.29-8.85-9.78-8.93-3.61-3.28-3.64-2.61-2.09-0.19-1.42-0.86
Shares Outstanding (Quarter)
0.05M0.05M0.40M1.95M1.96M1.96M1.96M1.96M1.96M1.97M1.96M1.99M4.13M4.53M3.82M5.34M6.89M10.29M8.36M16.35M
Shares Outstanding (Entity) (Quarter)
0.40M1.96M1.96M1.96M1.96M1.96M1.97M1.97M1.97M1.99M4.13M4.53M3.27M5.34M6.89M10.29M8.36M16.35M
EBITDA (Quarter)
-23.01M-15.96M-19.56M-21.22M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Interest Expenses (Quarter)
0.10M15.79M0.10M0.20M0.27M0.22M1.25M0.21M0.08M0.04M1.08M0.31M0.17M0.10M0.28M0.06M0.04M0.07M0.03M0.02M